Evidence map›Paper›PMID 30385844›Full record

ArticleScientific reports2018

Enhanced pharmacological efficacy of sumatriptan due to modification of its physicochemical properties by inclusion in selected cyclodextrins.

Magdalena Paczkowska, Mikołaj Mizera, Kinga Sałat, Anna Furgała, Piotr Popik, Justyna Knapik-Kowalczuk, Anna Krause, Daria Szymanowska-Powałowska, Zbigniew Fojud, Maciej Kozak and 2 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.5field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 1 country.

Magdalena PaczkowskaDepartment of Pharmacognosy, Poznań University of Medical Sciences, Święcickiego 4, 60-781, Poznań, Poland.
Mikołaj MizeraDepartment of Pharmacognosy, Poznań University of Medical Sciences, Święcickiego 4, 60-781, Poznań, Poland.
Kinga SałatDepartment of Pharmacodynamics, Jagiellonian University Medical College, Medyczna 9, 30-688, Kraków, Poland.
Anna FurgałaDepartment of Pharmacodynamics, Jagiellonian University Medical College, Medyczna 9, 30-688, Kraków, Poland.
Piotr PopikFaculty of Health Sciences, Jagiellonian University Medical College, Michałowskiego 12, 31-126, Kraków, Poland.
Justyna Knapik-KowalczukInstitute of Physics, University of Silesia, Uniwersytecka 4, 40-007, Katowice, Poland.
Anna KrausePozlab sp. z o.o., Parkowa 2, 60-775, Poznań, Poland.
Daria Szymanowska-PowałowskaDepartment of Biotechnology and Food Microbiology, Poznań University of Life Sciences, Wojska Polskiego 48, 60-627, Poznań, Poland.
Zbigniew FojudDepartment of Macromolecular Physics, Adam Mickiewicz University in Poznań, Umultowska 85, 61-614, Poznań, Poland.
Maciej KozakDepartment of Macromolecular Physics, Adam Mickiewicz University in Poznań, Umultowska 85, 61-614, Poznań, Poland.
Marian PaluchInstitute of Physics, University of Silesia, Uniwersytecka 4, 40-007, Katowice, Poland.
Judyta Cielecka-PiontekDepartment of Pharmacognosy, Poznań University of Medical Sciences, Święcickiego 4, 60-781, Poznań, Poland. jpiontek@ump.edu.pl.
Jagiellonian University · PLPoznan University of Medical Sciences · PLAdam Mickiewicz University in Poznań · PLInstitute of Physics · PLUniversity of Life Sciences in Poznań · PLUniversity of Silesia in Katowice · PL

Funding

Ministerstwo Nauki i Szkolnictwa Wyższego (Ministry of Science and Higher Education) DI2012 024342Uniwersytet Jagielloński Collegium Medicum (Jagiellonian University Medical College) K/ZDS/006281
6 · The paper itself

Abstract

The study focused on the pharmacological action of sumatriptan, in particular its antiallodynic and antihyperalgesic properties, as an effect of cyclodextrinic inclusion of sumatriptan, resulting in changes of its physicochemical qualities such as dissolution and permeability through artificial biological membranes, which had previously been examined in vitro in a gastro-intestinal model. The inclusion of sumatriptan into β-cyclodextrin and 2-hydroxylpropylo-β-cyclodextrin by kneading was confirmed with the use of spectral (fourier-transform infrared spectroscopy (FT-IR); solid state nuclear magnetic resonance spectroscopy with magic angle spinning condition,

Indexed as

beta-CyclodextrinsCalorimetry, Differential ScanningChromatography, High Pressure LiquidCyclodextrinsDrug CompoundingHumansHyperalgesiaMagnetic Resonance SpectroscopyMicroscopy, Electron, ScanningPermeabilitySolubilitySpectroscopy, Fourier Transform InfraredSumatriptanX-Ray Diffractionbeta-CyclodextrinsbetadexCyclodextrinsSumatriptan

Identifiers

PMID30385844
PMCPMC6212534
OpenAlexW2898411078

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.